Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone973-605-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.16 million
Profitability
Miscellaneous
Employees346
Next Earnings Date8/22/2019 (Estimated)
OptionableOptionable
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) issued its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.10. During the same period last year, the firm earned ($0.21) earnings per share. View Immunomedics' Earnings History.
When is Immunomedics' next earnings date?
What price target have analysts set for IMMU?
10 analysts have issued 1-year price objectives for Immunomedics' stock. Their forecasts range from $18.00 to $40.00. On average, they anticipate Immunomedics' stock price to reach $29.20 in the next year. This suggests a possible upside of 97.3% from the stock's current price. View Analyst Price Targets for Immunomedics.
What is the consensus analysts' recommendation for Immunomedics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.
What are Wall Street analysts saying about Immunomedics stock?
Here are some recent quotes from research analysts about Immunomedics stock:
- 1. According to Zacks Investment Research, "Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. " (5/14/2019)
- 2. HC Wainwright analysts commented, "We continue to expect a Class 2 resubmission—which is associated with a six-month review period—and, therefore, anticipate a potential market entry in 2Q20 (compared to our previous estimate of late 4Q19); the effect this had on our price target was negligible as we only forecasted a very small market penetration in 4Q19. Instead, the change from $29 to $28 is mainly being driven by a delay in the timing of receipt of the $60M dollar milestone payment by Everest Medicines associated with sacituzumab’s FDA approval in mTNBC (please see our prior note), and slightly increased projected R&D expenditures. Overall, we remain confident in IMMU-132’s efficacy profile and reiterate our Buy rating while lowering our price target to $28 from $29. Phase 3 TROPICS-02 trial may support accelerated approval." (5/13/2019)
Has Immunomedics been receiving favorable news coverage?
News coverage about IMMU stock has been trending negative recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Immunomedics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the next few days.
Are investors shorting Immunomedics?
Immunomedics saw a decrease in short interest in April. As of April 30th, there was short interest totalling 31,699,784 shares, a decrease of 8.3% from the April 15th total of 34,563,322 shares. Based on an average daily trading volume, of 2,513,740 shares, the days-to-cover ratio is currently 12.6 days. Approximately 18.6% of the company's stock are short sold. View Immunomedics' Current Options Chain.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB) and Celldex Therapeutics (CLDX).
What other stocks do shareholders of Immunomedics own?
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
- Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
- Mr. Scott A. Canute MBA, Exec. Director (Age 58)
- Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
- Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)
Who are Immunomedics' major shareholders?
Immunomedics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (11.94%), BlackRock Inc. (6.55%), ArrowMark Colorado Holdings LLC (2.11%), Janus Henderson Group PLC (2.01%), Jennison Associates LLC (1.59%) and TimesSquare Capital Management LLC (1.21%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Which major investors are selling Immunomedics stock?
IMMU stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Morgan Stanley, Schonfeld Strategic Advisors LLC, Man Group plc, TD Asset Management Inc., BlackRock Inc., Goldman Sachs Group Inc. and AQR Capital Management LLC. View Insider Buying and Selling for Immunomedics.
Which major investors are buying Immunomedics stock?
IMMU stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, TimesSquare Capital Management LLC, Fiera Capital Corp, Frontier Capital Management Co. LLC, Macquarie Group Ltd., Rice Hall James & Associates LLC, Jennison Associates LLC and QVT Financial LP. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy shares of Immunomedics?
Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of IMMU stock can currently be purchased for approximately $14.80.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $2.83 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.
What is Immunomedics' official website?
How can I contact Immunomedics?
Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
